Services · the whole catalogue

All services, side by side

What each one is, who it is for, when it applies, and what it cannot do. In one table, so you do not have to open six pages to compare two things.

Find your situation instead Book a free consultation

01What, who, when

Everything, in one table

Six product families, fourteen ways in. The table below is the whole catalogue in one place, so the question “what is the difference between these two” does not require opening six pages.

Service	What it is	Who it is for	When	Sample	What you get
Signal	One question, answered by a person on WhatsApp	Anyone, at any stage	Any time. Start here if unsure	None	A human-guided reply within four hours, free
Navigation	Your existing records turned into a clarity timeline	Anyone whose paperwork has outgrown them	Before a decision, or before a second opinion	Existing records	A timeline and roadmap you can hand to any clinician
Blueprint Care	The decision report and a dedicated clinical team	Anyone facing a treatment decision	At diagnosis, or when treatment changes	Comes with a Signature test or Decipher	A ranked, evidence-tiered plan signed by a tumour board
Decipher	Interpretation of sequencing done elsewhere	Anyone already tested but not answered	When you hold a report you cannot act on	Your existing data. No new sample	Full interpretation and board sign-out, without resequencing
Decipher Plus	Topping up only the gaps, then interpreting	Where an earlier panel missed something material	When prior testing was too narrow	Existing data plus a targeted top-up	The same report, with the gap filled rather than the test repeated
Signature STb	A 33-gene panel from a blood draw	A focused first molecular question	Before a treatment decision	Blood	Variants, therapy matching and a signed decision report
Signature STb O	A 118-gene panel from a blood draw	Broader profiling without tissue	Before a treatment decision	Blood	Wider coverage including fusion genes
Signature STb O+	A 523-gene comprehensive panel	When the whole molecular picture matters	Advanced disease, or a complex decision	Blood	Comprehensive profiling with TMB, MSI and pharmacogenomics
Signature STt O	Comprehensive profiling from tissue	Where a tumour block already exists	When tissue is available and adequate	An existing FFPE tissue block	Tissue-based comprehensive profiling
Signature B ALL and B AML	Profiling for blood cancers	Lymphoblastic and myeloid leukaemia	At diagnosis, and again at relapse	Blood or bone marrow	Leukaemia-specific molecular characterisation
Sentinel	Serial monitoring while treatment runs	Anyone on active treatment	Every few weeks or months, alongside scans	Blood, repeated	A trend line showing response and emerging resistance
Clear	Surveillance after curative-intent treatment	Anyone who has finished treatment	On a schedule, for years afterwards	Blood, repeated	Molecular residual disease surveillance
Heritage Core	A broad inherited-risk assessment	The person diagnosed, or someone at risk	When a cancer looks like it runs in the family	Blood or saliva	Germline result with genetic counselling
Heritage Adhoc	Focused testing for named relatives	Relatives of someone with a known alteration	Once the family alteration is identified	Blood or saliva	A yes or no on one specific variant, with counselling

Prices are confirmed at a free consultation, because the right tier depends on the question being asked. Published figures: Signature STb ₹1,50,000 including the decision report and board review; Heritage ₹50,000 index test then ₹35,000 per family member; Sentinel ₹88,000 to ₹1,00,000 per monitoring draw.

02Choosing between them

The questions people actually ask

Sentinel or Clear?

Sentinel watches during active treatment: is this working, is resistance emerging. Clear watches after treatment given with curative intent: is anything left, is it coming back. Same technology, different question, different schedule.

Signature or Decipher?

Signature generates new sequencing. Decipher interprets sequencing that already exists. If you have been tested properly and recently, Decipher is usually the cheaper and faster route to the same answer.

Which Signature tier?

It depends on the question, not on the budget. A focused question about a well-defined driver may be answered by 33 genes. A complex case with few standard options is where 523 genes earns its cost. Our consultation exists to work that out honestly.

Heritage or Signature?

Heritage tests what you inherited, from blood or saliva, and the answer concerns your relatives as much as you. Signature tests what the tumour acquired. They answer different questions and one does not substitute for the other.

Blood or tissue?

Blood is easier and repeatable but depends on the tumour shedding enough DNA. Tissue is the conventional reference but needs an adequate sample and cannot be repeated casually. In several cancers the two are used together rather than sequentially.

Do I need any of this?

Sometimes not. In some cancers and at some stages, molecular profiling will not change what happens next, and we would rather tell you that at a free consultation than take your money to confirm it.

03How they fit together

The shape of the journey

At diagnosis, or a treatment changeBlueprint Care with a Signature test, or Decipher if sequencing already exists. This is the decision point, and the one where timing matters most.
While treatment is runningSentinel, at two, four or six draws a year depending on how closely the situation needs watching.
After treatment given with curative intentClear, on a schedule matched to the cancer type and the follow-up plan.
Whenever inherited risk is raisedHeritage for the person diagnosed, then Heritage Adhoc for relatives once a family alteration is known.
At any point, at no costSignal for a question, Navigation to organise records, and a free consultation to work out whether any of this applies.

Diagram to come

One journey, and where each service sits on it

Ratio21/9

Design briefWanted for launch

A single timeline running from diagnosis through treatment and beyond, with each service placed at the point it applies. This is the page's whole argument in one picture: the services are not a menu of alternatives, they are stages of one path.

Horizontal vector timeline on the dark band, mint rule with brand purple markers. Reflows to a vertical rail below 720px rather than shrinking.

Must be in frame

Every service positioned at the point in the journey it applies
The free entry points, Signal and the consultation, marked as available at any point rather than at one stage
Heritage shown branching sideways to relatives, because it is the one service that is not about the patient alone

Must not be

Implying everyone moves through every stage
Any duration or survival figure on the axis

Draft alt text: A timeline from diagnosis onward with each OnKommon service placed at the stage it applies, and Heritage branching sideways to family members.

Find your situation Book a free consultation

04Stated plainly

What none of these do

What we DO

Tell you what is present, how strong the evidence is, and who signed for it
State the limits of the method used, including what it could not have detected
Map every recommendation to biosimilars, assistance programmes and schemes in India
Say when a test would not change anything, before you pay for it

What we DON’T do

Diagnose, prescribe, or replace your treating oncologist
Let software have the final word on anything clinically consequential
Guarantee a drug is available, approved, affordable or effective for you
Rule out disease on the strength of a “not detected” result

Take the next step

Three ways forward. Pick the one that fits today.

Book a free consultation

A no-obligation conversation with our care team, arranged through KPCIRC.

Book a consultation

Begin Blueprint Care

Commission your decision report and a dedicated clinical team.

Explore Blueprint Care

Ask on WhatsApp, free

Signal replies to your first question within four hours, at no cost.

Start with Signal